A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis

Anti-Cancer Drugs

Volumn 17, Issue 2, 2006, Pages 217-224

  Bethune Volters, Anne ^b   Chidiac, Jean ^c   Bensaoula, Okba ^b   Delgado, Antonio ^d   Di Palma, Mario ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE RENÉ HUGUENIN   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d Schwarz Pharma   (France)

Author keywords

Delayed emesis; Metopimazine; Ondansetron

Indexed keywords

ALIZAPRIDE; CARBOPLATIN; CISPLATIN; CLORAZEPATE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANISETRON; IRINOTECAN; METHYLPREDNISOLONE; METOCLOPRAMIDE; METOPIMAZINE; ONDANSETRON; OXALIPLATIN; PREDNISOLONE;

ABDOMINAL PAIN; ABSCESS; ADULT; AGED; ALOPECIA; ARTICLE; ASTHENIA; CANCER; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; FEMALE; FLUSHING; GASTROINTESTINAL DISEASE; HEADACHE; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; INTESTINE OBSTRUCTION; LARYNX EDEMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NAUSEA AND VOMITING; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH PAIN; VOMITING;

ADMINISTRATION, SUBLINGUAL; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISONIPECOTIC ACIDS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; NEOPLASMS; ONDANSETRON; QUALITY OF LIFE; QUESTIONNAIRES; VOMITING;

EID: 33646255672     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200602000-00014     Document Type: Article

References (28)

1. Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs 1996; 52:639-648.
2. Roila F, Donati D, Tamberi S, Margutti G. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002; 10:88-95.
3. 3 antagonist ondansetron with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 12:816-821.
4. De Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med 1990; 113:834-840.
5. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999; 17:2971-2994.
6. Multinational Association for Supportive Care in Cancer. Guidelines for antiemetic Drugs in Oncology. http://www.mascc.org. [Accessed June 2004].
7. Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Wertheim MS, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3:1379-1384.
8. Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M, et al. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol 1991; 14:238-242.
9. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15:103-109.
10. Federation Nationale des Centers de lutte Contre le Cancer. Standards, options and recommendations for the use of antiemetics in cancer [in French]. Paris: FNCCC; 1998. www.fnclcc.fr/fr/sor/pdf/rapport_integral/antiemetique_integrale_0397.pdf.
11. Pendergrass K, Hargreaves R, Petty KJ, Carides AD, Evans JK, Horgan KJ. Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy. Drugs Today 2004; 40:853-863.
12. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 1999; 340:190-195.
13. Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinsky ME, et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 1999; 17:338-343.
14. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993; 328:1076-1080 P.
15. Herrstedt J, Sigsgaard T, Handberg J, Schousboe BM, Hansen M, Dombernowsky P. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer. J Clin Oncol 1997; 15:1690-1696.
16. Herrstedt J. Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine. Dan Med Bull 1998; 45:412-422.
17. Sigsgaard T, Herrstedt J, Andersen LJ, Havsteen H, Langer SW, Kjaerbol AG, et al. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer 1999; 80:412-418.
18. Sigsgaard T, Herrstedt J, Christensen P, Andersen O, Dombernowsky P. Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy. Support Care Cancer 2000; 8:233-237.
19. Sigsgaard T, Herrstedt J, Handberg J, Kjaer M, Dombernowsky P. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as emetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemptherapy. J Clin Oncol 2001; 19:2091-2097.
20. Lebeau B, Depierre A, Giovannini M, Riviere A, Kaluzinski L, Votan B, et al. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group. Ann Oncol 1997; 8:887-892.
21. Bloch J, Rixe O, Meric JB, Delgado A, Khayat D. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. Curr Med Res Opin 2005; 21:1763-1771.
22. Casagrande JT, Pike MC. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 1978; 34:483-486.
23. Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R, et al. A randomized double blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethaxone in the prophylaxis of chemotherapy induced delayed emesis. Ann Oncol 2003; 14:291-297.
24. Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2005; 13:85-96.
25. Leverge R, Caulin C. Study of the relative and absolute bioavailability of metopimazine. Market Authorization File; 2003.
26. Clavel M, Bolot JE, Philippe-Bert J, Putot JP, Rodary C, Pommatau E. Essai comparatif en double insu de deux doses IV (50 et 10 mg) de métopimazine dans la prévention des nausées et des vomissements de la chimiothérapie anticancéreuse. Lyon Médical 1978; 239:307-309.
27. Moertel CG, Reitemeier RJ. Controlled studies of metopimazine for the treatment of nausea and vomiting. J Clin Pharmacol 1973; 13:283-287.
28. Israel I, Rodary C. Treatment of nausea and vomiting related to anti-cancerous multiple combination chemotherapy. J Int Med Res 1978; 6:235-240.